Abilify Tablet Indications/Uses

Schizophrenia: The efficacy of Abilify in the treatment of schizophrenia was established in short-term (4- and 6-week) controlled trials of schizophrenic inpatients (see Pharmacology under Actions). The efficacy of Abilify in maintaining stability in patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of ≥3 months were discontinued from those other medications, and were then administered Abilify 15 mg/day and observed for relapse during a period of up to 26 weeks was demonstrated in a placebo-controlled trial (see Pharmacology under Actions). The physician who elects to use Abilify for extended periods should periodically re-evaluate the long-term usefulness of Abilify for the individual patient (see Dosage & Administration).
Bipolar Disorder: Treatment of acute manic and mixed epithelial episodes associated with bipolar disorder. The efficacy of Abilify was established in 2 placebo-controlled trials (3 weeks) of inpatient with DSM-IV criteria for bipolar I disorder who were expecting an acute manic or mixed episodes with or without psychotic features (see Pharmacology under Actions). The efiicacy of Abilify in maintaining efficacy in patients with bipolar I disorder with a recent manic or mixed episode who had been stabilized and then maintained for at least 6 weeks was demonstrated in a double-blind, placebo-controlled trial. Prior to entering the double-blind, randomization phase of this trial, patients were clinically stabilized for 6 consecutive weeks on Abilify. Following this 6-week maintenance phase, patients were randomized to either placebo or Abilify and monitored for relapse (see Pharmacology under Actions).
Physicians who elect to use Abilify for extended periods ie, >6 weeks, should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Dosage & Administration).
Adjunctive therapy for major depressive disorder.